We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
West is pleased to announce new extensions of the SmartDose® drug delivery platform, including several new wearable injectors that allow for up to 10 mL of volume to be injected in easy-to-use, wearable formats. The new devices were showcased at the annual PDA Universe of Pre-filled Syringes and Injection Devices conference in Vienna, Austria, in November.
“Advancements in drug development need to be paired with advances in drug delivery, such as last year’s FDA approval of the first combination product using our SmartDose drug delivery platform. Based on this technology, we are now excited to share our expanded portfolio of SmartDose wearable injectors,” said Eric Resnick, Vice President and Chief Technology Officer at West in a recent press release. “As our customers continue to innovate and bring to market exciting new therapies to address important unmet medical needs, West is ready to help them with advancements in drug containment and delivery and technical expertise to guide them through the drug development and approval process.”
West's SmartDose drug delivery platform allows patients to self-administer medication in accordance with their prescribed treatment. West developed this wearable device with extensive human factors testing and analysis to understand the interaction between the patient and the delivery system. All versions of the SmartDose platform adhere to the patient's body, usually on the abdomen, so patients can be hands free during administration.
The SmartDose platform offers an variety of integrated solutions for delivery and containment featuring a Daikyo Crystal Zenith® cartridge and a FluroTec® coated piston containment system. West has built upon the success of the Generation (Gen. I) device to address market needs for higher dose volumes and enhanced functionality and usability.
West now offers the following options for development:
For more information about any of the SmartDose drug delivery platform devices or self-injection systems, contact West today.
When combined with the industry trends of increased regulatory scrutiny and higher focus on patient safety, risk management, and compliance, the market is seeing an increased need for high-quality drug delivery systems such as prefillable syringes.
Drug products such as biologics, vaccines and products whose chemical and physio-chemical stability depends on temperature put an added emphasis on pharmaceutical manufacturers to ensure proper handling, storage, transportation and dispensing. Maintaining a secure “cold chain” during the storage, handling and transportation of temperature-sensitive drugs, vaccines and blood products not only assures product quality and integrity for the benefit of the patient, but also helps to keep the manufacturer, hospital, pharmacist, physician and nurse in compliance with various laws, regulations, guidelines and codes.
For the 2012 West without Borders campaign, the headquarters team selected to support Caron Treatment Centers, a nationally recognized non-profit provider of alcohol and drug addiction treatment. With experience in treating co-occurring disorders, Caron offers comprehensive treatment programs for adolescents, young adult, adults and their families. Its mission is to provide an enlightened, caring treatment community in which all those affected by alcoholism or drug addiction may begin a new life. Caron is based in Wernersville, Pa.
To continue to learn and innovate is truly a daunting task. The journey to success has many ups and downs, but the end of that journey is not necessarily about knowing what worked or did not, but what to do with those learnings. In West’s journey to becoming a world leader in integrated containment and delivery (i.e., our learning experience), we continue to focus on market needs and listen to the voice of the customer. There are few better places to engage with customers and learn about the state of an industry than a trade show or conference. Below are some learnings (Part 1) – first-hand accounts of changes and trends that are shaping the pharmaceutical landscape that have been the topic of conversation at recent shows. Stay tuned for Parts 2 and 3.<p> </p>
Many of the top-selling biologic drug products will soon come off-patent. As a result, according to IMS, the biosimilar market is expected to reach between US$1.9-2.6 billion by 2015.
English
Chinese
